読み込み中
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
前日終値
$4.11
−$0.07 · -1.67%
日中の時刻はETです。市場データは遅延する場合があります。
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
日中レンジ
現在 $4.11
52週レンジ
現在 $4.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
73
割安
センチメント
42
まちまち
リスク
69
高リスク
モメンタム
42
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
日中レンジ
現在 $4.11
52週レンジ
現在 $4.11
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3557.7万 USD | 756.6万 USD | 512.4万 USD | 903.2万 USD | 1200万 USD |
| 売上原価 | 344.1万 USD | 274万 USD | 74.6万 USD | 72.5万 USD | 47.2万 USD |
| 粗利益 | 3213.6万 USD | 482.6万 USD | 437.8万 USD | 830.7万 USD | 1152.8万 USD |
| 研究開発 | 885.5万 USD | 1184万 USD | 2029.5万 USD | 1219.8万 USD | 1592.9万 USD |
| 販売・一般管理 | 3522万 USD | 5882.2万 USD | 4730.5万 USD | 1740.5万 USD | 2697.9万 USD |
| 営業費用 | 4407.5万 USD | 7074.5万 USD | 7013.7万 USD | 2960.3万 USD | 4243.6万 USD |
| 受取利息 | 92.9万 USD | 141.7万 USD | 274万 USD | 47.6万 USD | 12.3万 USD |
| 支払利息 | 774.2万 USD | 941.2万 USD | 396.2万 USD | 217.2万 USD | 429.5万 USD |
| 減価償却費と償却費 | 78.1万 USD | 126.9万 USD | 83.6万 USD | 71.8万 USD | 47.2万 USD |
| 営業利益 | −1193.9万 USD | −6591.9万 USD | −6575.9万 USD | −2129.6万 USD | −3090.8万 USD |
| 純利益 | −1788.6万 USD | −7657.9万 USD | −6699.5万 USD | −2448.7万 USD | −3508万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$9.00
上昇余地（118.98%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Avantis Total Equity Markets ETF 1AVTMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
